These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 27518890

  • 1. Quantitation of anticancer drugs - Cyclophosphamide and ifosfamide in urine and water sewage samples by gas chromatography-mass spectrometry.
    Lekskulchai V.
    Int J Occup Med Environ Health; 2016; 29(5):815-22. PubMed ID: 27518890
    [Abstract] [Full Text] [Related]

  • 2. Determination of cyclophosphamide and ifosfamide in sewage effluent by stable isotope-dilution liquid chromatography-tandem mass spectrometry.
    Llewellyn N, Lloyd P, Jürgens MD, Johnson AC.
    J Chromatogr A; 2011 Nov 25; 1218(47):8519-28. PubMed ID: 22014384
    [Abstract] [Full Text] [Related]

  • 3. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide.
    Minoia C, Turci R, Sottani C, Schiavi A, Perbellini L, Angeleri S, Draicchio F, Apostoli P.
    Rapid Commun Mass Spectrom; 1998 Nov 25; 12(20):1485-93. PubMed ID: 9796535
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of environmental contaminations and occupational exposures involved in preparation of chemotherapeutic drugs.
    Maeda S, Miyawaki K, Matsumoto S, Oishi M, Miwa Y, Kurokawa N.
    Yakugaku Zasshi; 2010 Jun 25; 130(6):903-10. PubMed ID: 20519870
    [Abstract] [Full Text] [Related]

  • 5. Highly sensitive high-performance liquid chromatography/selective reaction monitoring mass spectrometry method for the determination of cyclophosphamide and ifosfamide in urine of health care workers exposed to antineoplastic agents.
    Sottani C, Tranfo G, Faranda P, Minoia C.
    Rapid Commun Mass Spectrom; 2005 Jun 25; 19(19):2794-800. PubMed ID: 16144038
    [Abstract] [Full Text] [Related]

  • 6. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital.
    Hedmer M, Tinnerberg H, Axmon A, Jönsson BA.
    Int Arch Occup Environ Health; 2008 Jul 25; 81(7):899-911. PubMed ID: 18066576
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation.
    Sottani C, Rinaldi P, Leoni E, Poggi G, Teragni C, Delmonte A, Minoia C.
    Rapid Commun Mass Spectrom; 2008 Sep 25; 22(17):2645-59. PubMed ID: 18666202
    [Abstract] [Full Text] [Related]

  • 9. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry.
    Schmaus G, Schierl R, Funck S.
    Am J Health Syst Pharm; 2002 May 15; 59(10):956-61. PubMed ID: 12040735
    [No Abstract] [Full Text] [Related]

  • 10. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: A 2016 follow-up study.
    Roland C, Caron N, Bussières JF.
    J Occup Environ Hyg; 2017 Aug 15; 14(8):661-669. PubMed ID: 28574754
    [Abstract] [Full Text] [Related]

  • 11. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals.
    Poupeau C, Tanguay C, Caron NJ, Bussières JF.
    J Oncol Pharm Pract; 2018 Jan 15; 24(1):9-17. PubMed ID: 27799608
    [Abstract] [Full Text] [Related]

  • 12. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents.
    Wick C, Slawson MH, Jorgenson JA, Tyler LS.
    Am J Health Syst Pharm; 2003 Nov 15; 60(22):2314-20. PubMed ID: 14652980
    [Abstract] [Full Text] [Related]

  • 13. Human metabolites and transformation products of cyclophosphamide and ifosfamide: analysis, occurrence and formation during abiotic treatments.
    Česen M, Kosjek T, Busetti F, Kompare B, Heath E.
    Environ Sci Pollut Res Int; 2016 Jun 15; 23(11):11209-11223. PubMed ID: 26920534
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of a procedure for the simultaneous quantification of 4-ketocyclophosphamide, cyclophosphamide, and Ifosfamide in human urine.
    B'Hymer C, Cheever KL.
    J Chromatogr Sci; 2010 Jun 15; 48(5):328-33. PubMed ID: 20515523
    [Abstract] [Full Text] [Related]

  • 15. Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry.
    Sannolo N, Miraglia N, Biglietto M, Acampora A, Malorni A.
    J Mass Spectrom; 1999 Aug 15; 34(8):845-9. PubMed ID: 10423565
    [Abstract] [Full Text] [Related]

  • 16. [The determination of urinary cyclophosphamide at low concentration levels by liquid-liquid extraction and HPLC/MS/MS analysis].
    Sottani C, Turci R, Perbellini L, Minoia C.
    G Ital Med Lav Ergon; 1998 Aug 15; 20(4):239-42. PubMed ID: 9987616
    [Abstract] [Full Text] [Related]

  • 17. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters.
    Buerge IJ, Buser HR, Poiger T, Müller MD.
    Environ Sci Technol; 2006 Dec 01; 40(23):7242-50. PubMed ID: 17180973
    [Abstract] [Full Text] [Related]

  • 18. Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water.
    Kümmerer K, Al-Ahmad A.
    Environ Sci Pollut Res Int; 2010 Feb 01; 17(2):486-96. PubMed ID: 19548016
    [Abstract] [Full Text] [Related]

  • 19. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs.
    Ensslin AS, Stoll Y, Pethran A, Pfaller A, Römmelt H, Fruhmann G.
    Occup Environ Med; 1994 Apr 01; 51(4):229-33. PubMed ID: 8199663
    [Abstract] [Full Text] [Related]

  • 20. Quantification of healthcare workers' exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study.
    Palamini M, Dufour A, Therrien R, Delisle JF, Mercier G, Gagné S, Caron N, Bussières JF.
    J Oncol Pharm Pract; 2020 Dec 01; 26(8):1864-1870. PubMed ID: 32138611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.